January 4th, 2018
The World Health Organisation (WHO) has given its pre-qualification to Typbar Typhoid Conjugate Vaccine (TVC) developed by Hyderabad based Bharat Biotech for global use. Typbar TCV is world’s first typhoid vaccine clinically proven to be administered to children from six months of age to adults, and confers long-term protection against typhoid fever. It has been evaluated in Human Challenge Studies at Oxford University.